, and genetically engineered mouse models to address a causal connection are lacking. Here we functionally probe the role of EMT in PDAC by generating mouse models of PDAC with deletion of Snail or Twist, two key transcription factors responsible for EMT. EMT suppression in the primary tumour does not alter the emergence of invasive PDAC, systemic dissemination or metastasis. Suppression of EMT leads to an increase in cancer cell proliferation with enhanced expression of nucleoside transporters in tumours, contributing to enhanced sensitivity to gemcitabine treatment and increased overall survival of mice. Collectively, our study suggests that Snail-or Twist-induced EMT is not rate-limiting for invasion and metastasis, but highlights the importance of combining EMT inhibition with chemotherapy for the treatment of pancreatic cancer.
. EMT is associated with phenotypic conversion of epithelial cells into mesenchymallike cells in cell culture conditions, although such defined mesenchymal conversion (with spindle-shaped morphology) of epithelial cells in vivo is rare, with quasi-mesenchymal phenotypes occasionally observed in the tumour (partial EMT) 5, 6 .
Most studies exploring the functional role of EMT in tumours have depended on cell-culture-induced loss-of-function and gain-of-function experiments involving EMT-inducing transcription factors such as Twist, Snail and Zeb1 (refs 2,3,7-10)
. Therefore, the functional contribution of EMT to invasion and metastasis remains unclear 4, 6 , and genetically engineered mouse models to address a causal connection are lacking. Here we functionally probe the role of EMT in PDAC by generating mouse models of PDAC with deletion of Snail or Twist, two key transcription factors responsible for EMT. EMT suppression in the primary tumour does not alter the emergence of invasive PDAC, systemic dissemination or metastasis. Suppression of EMT leads to an increase in cancer cell proliferation with enhanced expression of nucleoside transporters in tumours, contributing to enhanced sensitivity to gemcitabine treatment and increased overall survival of mice. Collectively, our study suggests that Snail-or Twist-induced EMT is not rate-limiting for invasion and metastasis, but highlights the importance of combining EMT inhibition with chemotherapy for the treatment of pancreatic cancer.
We Fig. 1b ) and insignificant differences in overall survival (Fig. 1d) . Loss of Twist1 or Snai1 expression in the pancreas epithelium was confirmed by in situ hybridization coupled with CK8 epithelial immunolabelling ( Fig. 1e and Extended Data Fig. 1c ) as well as immunolabelling for Twist and Snail (Extended Data Fig. 1d ). Significant suppression of EMT was noted (Fig. 1f, g and Extended Data Fig. 1e , f). Lineage tracing (Fig. 1f and Extended Data Fig. 1e ) and immunolabelling of the primary tumour (Fig. 1g) showed a significant decrease in the frequency of epithelial cells with expression of the mesenchymal marker α SMA (EMT + cells) and a decrease in expression of the EMT-inducing transcription factor Zeb1 (Fig. 1h) . Global gene expression profiling of tumours revealed a decrease in expression of EMT-associated genes (including Snai1 and Twist1) in KPC;Snail cKO and KPC;Twist cKO mice compared to KPC control (Extended Data Fig. 1f ). Loss of Snail and Twist enhanced E-cadherin expression and suppressed Zeb2 and Sox4 expression in cancer cells (Extended Data Fig. 2a-c) . Snai2 (Slug) expression was restricted to early pancreatic intraepithelial neoplasia (PanIN) lesions in all the experimental groups with no observed expression in advanced tumours and was significantly reduced in KPC;Snail cKO and KPC;Twist cKO mice compared to KPC control mice (Extended Data Fig. 2d ).
While desmoplasia, including extracellular matrix (ECM) and myofibroblasts content ( Fig. 1i and Extended Data Fig. 2e, f) , tumour vessel density (Extended Data Fig. 2g ), intratumoural hypoxia (Extended Data Fig. 2h ), CD3
+ T-cell infiltration (Extended Data Fig. 2i ), and cancer cell apoptosis was unaffected with Twist/Snail deletion in KPC tumours (Fig. 2a) , the proliferation of cancer cells in mice with suppressed EMT was significantly increased (Fig. 2b) , as shown previously in mouse models of breast cancers [11] [12] [13] . Immunostaining experiments further revealed that EMT + cancer cells are largely Ki67 − (Extended Data Fig. 3a) . Altogether, these data suggest that EMT driven by Twist/Snail transcription factors is dispensable for initiation and progression of primary pancreatic cancer.
Next, we investigated whether suppression of EMT impacts invasion and metastasis. The number of YFP + circulating tumour cells from lineage-traced KPC and KPC;Twist cKO was found to be unchanged ( Fig. 2c and Extended Data Fig. 3b ), and expression of cancer-cell-specific Kras G12D mRNA in the blood from KPC, KPC;Twist cKO and KPC;Snail cKO mice was unaffected (Fig. 2d) , suggesting that suppression of EMT in pancreatic tumours does not impact the rate of systemic dissemination of cancer cells. Extensive histopathological analyses, coupled with CK19 or YFP immunostaining of distant metastatic target organs, namely the liver, lung and spleen, indicated a similar frequency of metastasis in EMT-suppressed tumours when compared to control tumours (Fig. 2e, Extended Data Fig. 3c and Extended Data Tables 1 and 2 ). The metastases were negative for Twist, Snail, Zeb1 and α SMA, with the exception of a few KPC metastatic cells that expressed α SMA or Zeb1 (Extended Data Fig. 3d-f ),
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© 2015 Macmillan Publishers Limited. All rights reserved while being positive for E-cadherin and Ki-67 (Extended Data Fig. 3g, h ). The proliferation rate of cancer cells in the metastases was similar in KPC, KPC;Snail cKO and KPC;Twist cKO mice (Extended Data   Fig. 3h) . Collectively, the results indicated that the deletion of Twist1 or Snai1 in genetically engineered mouse models of PDAC did not reduce metastatic disease. . Unless otherwise indicated error bars represent s.e.m., percentages represent per cent change from control and significance was determined by one-way ANOVA. * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001; NS, not significant.
To evaluate whether cancer cells from the pancreas with and without EMT program differentially benefited from impaired proliferation to form secondary tumours, we isolated cancer cells from KPC, KPC;Twist cKO and KPC;Snail cKO mice to assay their organ colonization potential. Twist1 was significantly reduced and Snai1 expression was undetectable in cancer cells isolated from Twist-and Snail-deleted tumours, respectively (Fig. 2f ). Short-term potential to form tumour spheres (associated with putative cancer stem phenotype) appeared similar in Twist cKO and Snail cKO KPC cells when compared to control KPC cells (Fig. 2g ) 3, 8, [14] [15] [16] . Lung colonization frequencies following i.v. injection of KPC cancer cells (Twist-or Snail-deleted) were similar to the control KPC cancer cells (Fig. 2h) . These results suggest that a favoured epithelial phenotype of cancer cells (via suppression of EMT) did not impact the capacity to form tumour spheres or their ability for organ colonization 17 . Cancer cell EMT is associated with gemcitabine drug resistance in PDAC patients and in the orthotopic mouse models of PDAC 1,2, 8, 9, [18] [19] [20] [21] [22] [23] . Moreover, enhanced frequency of EMT + cancer cells in pancreatic tumours is associated with poor survival 24, 25 . To determine whether EMT suppression enhances PDAC sensitivity to gemcitabine chemotherapy, we tested the gemcitabine sensitivity of cancer cells with suppressed EMT in KPC mice. Equilibrative nucleoside transporter (ENT1) and concentrating nucleoside transporter (Cnt3) were significantly upregulated in cancer cells lacking Snail and Twist, while ENT2 expression was unchanged ( Fig. 3a-c) . KPC, KPC;Snail cKO and KPC;Twist cKO mice were treated with gemcitabine and tumour burden was monitored by MRI (Extended Data Table 3 ). Tumour progression was suppressed in KPC;Snail cKO and KPC;Twist cKO mice when compared to treated KPC control mice (Fig. 3d ). KPC;Snail cKO and KPC;Twist cKO mice treated with gemcitabine showed improved histopathology and increased survival ( Fig. 3e-g ).
Cancer cells isolated from the tumours of KPC;Snail cKO and KPC;Twist cKO mice showed epithelial morphology (Extended Data Fig. 4a ) and reduced expression of mesenchymal genes compared to KPC cancer cell lines (Extended Data Fig. 4b ). However, in tissue culture conditions (2D culture on plastic), equilibrative nucleoside transporters (ENT1/ENT2/ ENT3) showed similar expression patterns (Extended Data A table presenting the number of colonized tissues out of total tissues examined is shown below (χ 2 analysis). Unless otherwise indicated error bars represent s.e.m and significance was determined by one-way ANOVA. * P < 0.05, * * P < 0.01, * * * * P < 0.0001; NS, not significant; ND, not detected.
© 2015 Macmillan Publishers Limited. All rights reserved the increased sensitivity to gemcitabine and erlotinib in this setting (Extended Data Fig. 4d) .
Next, we crossed the Snai1 L/L to the PDAC mouse model,
). The KTC model offers a reliable and penetrant disease progression rate with a consistent timeline of death due to PDAC. Similar to the KPC;Snail cKO mice, KTC;Snail cKO deletion exhibited suppression of EMT but did not affect primary tumour histopathology, lifespan, local invasion, desmoplasia or frequency of apoptosis ( Fig. 4f and Extended Data Figs 5a-e and 6a). KTC;Snail cKO mice presented with significantly reduced Zeb1 expression in cancer cells but enhanced expression of Cnt3, ENT2 and proliferation (Extended Data Fig. 5e ). ENT1 expression was unchanged in KTC;Snail cKO mice compared to KTC mice (Extended Data Fig. 6a ). KTC;Snail cKO mice demonstrated enhanced response to gemcitabine therapy, with significant normal parenchymal area and reduced tumour tissue (Fig. 4a-c) . Gemcitabine therapy in KTC;Snail cKO mice reduced tumour burden (Fig. 4d) and significantly improved overall survival (Fig. 4e ) when compared to gemcitabine-treated control KTC mice. Gemcitabine therapy specifically increased cancer cell apoptosis and removed enhanced proliferation observed in EMT-suppressed tumours ( Fig. 4g and Extended Data Fig. 5e) , without impacting the desmoplastic reaction (Extended Data Fig. 6b) . Overall, these results suggest an enhanced sensitivity of EMT-suppressed cancer cells to gemcitabine. Both ENT2 and Cnt3 were upregulated in EMT-suppressed tumours (Fig. 4g ). These data support a possible mechanistic connection between EMT and resistance to chemotherapy in PDAC.
Collectively, our studies provide a comprehensive functional analysis of EMT in PDAC progression and metastasis. Absence of either Twist1 or Snai1 did not alter cancer progression or the capacity for local invasion or metastasis to lung and liver in genetically engineered mouse models of PDAC. Metastasis occurs despite a significant loss of EMT with either the deletion of Snail or Twist, and in both settings, Zeb1, Sox4, Slug and Zeb2 are also significantly suppressed. Nevertheless, it is possible that other EMT-inducing factors may compensate for the loss of Snail or Twist to induce invasion and metastasis. While Pdx1 is expressed during the development of the pancreas (in early pancreatic buds and all three major lineages of the pancreas: ductal, acinar and β -islets), its expression is largely repressed in the adult exocrine pancreas 26, 27 . Therefore, deletion of Snail or Twist occurs at the embryonic stage and mice are born normal and exhibit normal pancreas histology before the onset of cancer. The mice with Snail or Twist deletion develop PanIN lesions at the same frequency as the control mice. One could argue that suppression of EMT starting from the inception of cancer could have launched compensatory mechanisms to overcome EMT-dependent invasion and metastasis. However, such compensation is not observed with respect to chemoresistance, and previous studies have demonstrated that EMT and cancer cell dissemination are observed even before PDAC lesions are detected in KPC mice 4 . Our study demonstrates that EMT results in suppression of cancer cell proliferation and suppression of drug transporter and concentrating proteins, therefore inadvertently protecting EMT + cells from anti-proliferative drugs such as gemcitabine. The correlation of decreased survival of pancreatic cancer patients with increased EMT is probably due to their impaired capacity to respond to gemcitabine and chemotherapeutics, which is a standard of care for most patients 28, 29 .
A compromised response to chemotherapy probably also explains higher metastatic disease in association with decreased survival of , ENT2 (n = 5 mice for both groups; scale bar, 100 μ m), and Cnt3 (n = 5 mice for both groups; scale bar, 100 μ m). Unless otherwise indicated error bars represent s.e.m. and significance was determined by two-tailed t-tests. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant. patients with enhanced EMT signatures. Collectively, our study offers the opportunity to evaluate the potential of targeting EMT to enhance efficacy of chemotherapy and targeted therapies 30 .
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. , KTC and KTC;Snail cKO mice and were maintained on a mixed genetic background. Both males and females were used indiscriminately. Mice were given gemcitabine (G-4177, LC Laboratories) via intraperitoneal injection (i.p.) every other day at 50 mg kg −1 of body weight. Hypoxyprobe was injected in a subset of mice i.p. at 60 mg kg −1 of body weight 30 min before euthanasia. For in vivo colonization assays, one million KPC, KPC;Twist cKO and KPC;Snail cKO tumour cells in 100 μ l of PBS were injected intravenously via the retro-orbital venous sinus. Four to eleven mice were injected per cell line. All mice were euthanized at 15 days post injection. All mice were housed under standard housing conditions at MD Anderson Cancer Center (MDACC) animal facilities, and all animal procedures were reviewed and approved by the MDACC Institutional Animal Care and Use Committee. Tumour growth met the standard of a diameter less than or equal to 1.5 cm. Investigators were not blinded to group allocation but were blinded for the assessment of the phenotypic outcome by histological analyses. No statistical methods were used to predetermine sample size and the experiments were not randomized. Histology and histopathology. Histology, histopathological scoring, Masson's trichrome staining (MTS), and Picrosirius Red have been previously described 19, 33 . Formalin-fixed tissues were embedded in paraffin and sectioned at 5 μ m thickness. MTS was performed using Gomori's Trichome Stain Kit (38016SS2, Leica Biosystems). Picrosirius red staining for collagen was performed using 0.1% picrosirius red (Direct Red80; Sigma) and counterstained with Weigert's haematoxylin. Sections were also stained with haematoxylin and eosin (H&E). Histopathological measurements were assessed by scoring H&E-stained tumours for relative percentages of each histopathological phenotype: normal (non-neoplastic), PanIN, well-differentiated PDAC, moderately-differentiated PDAC, poorly-differentiated PDAC, sarcomatoid carcinoma, or necrosis. When tumour histology was missing or of poor quality, the mice were excluded from primary tumour histological analysis and this was determined blinded from genotype information. A histological invasion score of the tumour cells into the surrounding stroma was scored on a scale of 0 to 2, with 0 indicating no invasion and 2 indicating high invasion, where invasion is defined as tumour cell dissemination throughout the stroma away from clearly defined epithelial 'nests' . Microscopic metastases were observed in H&E-stained tissue sections of the liver, lung and spleen. Positivity (one or more lesions in a tissue) was confirmed using CK19 and YFP immunohistochemistry. This data has been presented as a contingency table (Fig. 2e) and represented as the number of positive tissues out of the number of tissues scored. The ' Any' metastasis score is the number of mice positive for a secondary lesion found anywhere throughout the body out of the total number of mice scored. Immunohistochemistry and Immunofluorescence. Tissues were fixed in 10% formalin overnight, dehydrated, and embedded in paraffin and 5-μ m-thick sections were then processed for analyses. Immunohistochemical analysis was performed as described 33 . Heat-mediated antigen retrieval in 1 mM EDTA + 0.05% Tween20 (pH 8.0) for one hour (pressure cooker) was performed for Snail and Twist, 10 mM citrate buffer, pH 6.0, was used for one hour (microwave) for the Perkin Elmer 3DHistotech Slide Scanner. Fluorescence imagery was obtained on a Zeiss Axio Imager.M2 or the Perkin Elmer Vectra Multispectral imaging platform. The images were quantified for per cent positive area using NIH ImageJ analysis software (α SMA, Pimonidazole, Slug, and CD31), per cent positive cells using InForm analysis software (Ki67 and CD3), or scored for intensity either positive or negative (α SMA/CK8 dual staining, α SMA, CK19, YFP, Zeb1, Zeb2, Sox4, E-cadherin and cleaved caspase-3) or on a scale of 1-3 (E-cadherin) or 1-4 (ENT1, ENT2 and Cnt3). In situ hybridization. In situ hybridization (ISH) was performed on frozen tumour sections as previously described 34 . In brief, 10-μ m-thick sections were hybridized with antisense probes to Twist1 and Snai1 overnight at 65 °C. After hybridization, sections were washed and incubated with AP-conjugated sheep anti-DIG antibody (1:2,000; Roche) for 90 min at room temperature. After three washes, sections were incubated in BM Purple (Roche) until positive staining was seen. Digoxigenin-labelled in situ riboprobes were generated with an in vitro transcription method (Promega and Roche) using a PCR template. The following primers were used to generate the template PCR product. Twist1, forward, 5′ -CGGCCAGGTACATCGACTTC-3′ ; reverse, 5′ -TAATACG ACTCACTATAGGGAGATTTAAAAGTGTGCCCCACGC-3′ ; Snai1, forward, 5′ -CAACCGTGCTTTTGCTGAC-3′ ; reverse, 5′ -TAATACGACTCACTATAGG GAGACCTTTAAAATGTAAACATCTTTCTCC-3′. Gene expression profiling. Total RNA was isolated from tumours of KPC control, KPC;Twist cKO and KPC;Snail cKO mice (n = 3 in each group) by TRIzol (15596026, Life Technologies) and submitted to the Microarray Core Facility at MD Anderson Cancer Center. Gene expression analysis was performed using MouseWG-6 v2.0 Gene Expression BeadChip (Illumina). The Limma package from R Bioconductor 35 was used for quantile normalization of expression arrays and to analyse differentially expressed genes between cKO and control sample groups. Gene expression microarray data have been deposited in GEO (Accession number GSE66981). Genes upregulated in cells acquiring an EMT program were expected to be downregulated in the Twist cKO and Snail cKO tumours compared to control tumours. + cells from gated cells, with 100,000 cells analysed at the time of acquisition. Whole blood cell pellets were also assayed for the expression of Kras G12D transcripts, using quantitative real-time PCR analyses (described below). Primary pancreatic adenocarcinoma cell culture and analyses. Derivation of primary PDAC cell lines were performed as previously described 36 . Fresh tumours were minced with sterile razor blades, digested with dispase II (17105041, Gibco, 4 mg ml )/RPMI for 1 h at 37 °C, filtered by a 70 μ m cell strainer, resuspended in RPMI/20%FBS and then seeded on collagen I-coated plates (087747, Fisher Scientific). Cells were maintained in RPMI medium with 20% FBS and 1% penicillin, streptomycin and amphotericin B (PSA) antibiotic mixture. Cancer cells were further purified by FACS based on YFP or E-cadherin expression (anti-E-cadherin antibody, 50-3249-82, eBioscience, 1:100). The sorted cells, using BD FACSAria TM II sorter (South Campus Flow Cytometry Core Lab of MD Anderson Cancer Center) were subsequently expanded in vitro. All studies were performed on cells cultivated less than 30 passages. As these are primary cell lines, no further authentication methods were applicable and no mycoplasma tests were performed. MTT and drug sensitivity assays. MTT assay was performed to detect cell proliferation and viability by using Thiazolyl Blue Tetrazolium Bromide (MTT, M2128, Sigma) following the manufacturer's recommendations with an incubation of two hours at 37 °C. For the drug treatment studies, a cell line derived from each of the KPC, KPC;Snail cKO and KPC;Twist cKO mice was treated with 20 μ M gemcitabine (G-4177, LC Laboratories) or 100 μ M erlotinib (5083S, NEB) for 48 h. The relative cell viability was detected using MTT assay with a cell line derived from each of the KPC, KPC;Snail cKO and KPC;Twist cKO mice. n is defined as the number of biological replicates of a single cell line. Control conditions included 1% DMSO vehicle for erlotinib. The relative absorbance was normalized and control (time 0 h or vehicle-treated) arbitrarily set to 1 or 100% for absorbance or drug survival, respectively. Quantitative real-time PCR analyses (qPCR). RNA was extracted from whole blood cell pellets following ACK lysis using the PicoPure Extraction kit as directed (KIT0214, Arcturus), or from cultured primary pancreatic adenocarcinoma cells using TRIzol (15596026, Life Technologies). cDNA was synthetized using TaqMan Reverse Transcription Reagents (N8080234, 
